PMC:7161517 / 655-1012 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T3","span":{"begin":201,"end":205},"obj":"Body_part"},{"id":"T4","span":{"begin":246,"end":250},"obj":"Body_part"}],"attributes":[{"id":"A3","pred":"fma_id","subj":"T3","obj":"http://purl.org/sig/ont/fma/fma12520"},{"id":"A4","pred":"fma_id","subj":"T4","obj":"http://purl.org/sig/ont/fma/fma7195"}],"text":"agents may facilitate viral disease; thus, they should not be used in high-risk patients with cardiovascular disease. Based on the anti-inflammatory benefits of the upregulation of the ACE2/Ang1-7/Mas axis and previously demonstrated benefits of lung function improvement in SARS-CoV infections, it has been hypothesized that the benefits of treatment with "}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T2","span":{"begin":246,"end":250},"obj":"Body_part"}],"attributes":[{"id":"A2","pred":"uberon_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/UBERON_0002048"}],"text":"agents may facilitate viral disease; thus, they should not be used in high-risk patients with cardiovascular disease. Based on the anti-inflammatory benefits of the upregulation of the ACE2/Ang1-7/Mas axis and previously demonstrated benefits of lung function improvement in SARS-CoV infections, it has been hypothesized that the benefits of treatment with "}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T6","span":{"begin":22,"end":35},"obj":"Disease"},{"id":"T7","span":{"begin":94,"end":116},"obj":"Disease"},{"id":"T8","span":{"begin":275,"end":283},"obj":"Disease"},{"id":"T9","span":{"begin":284,"end":294},"obj":"Disease"}],"attributes":[{"id":"A6","pred":"mondo_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/MONDO_0005108"},{"id":"A7","pred":"mondo_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/MONDO_0004995"},{"id":"A8","pred":"mondo_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A9","pred":"mondo_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"}],"text":"agents may facilitate viral disease; thus, they should not be used in high-risk patients with cardiovascular disease. Based on the anti-inflammatory benefits of the upregulation of the ACE2/Ang1-7/Mas axis and previously demonstrated benefits of lung function improvement in SARS-CoV infections, it has been hypothesized that the benefits of treatment with "}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T4","span":{"begin":246,"end":250},"obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"T5","span":{"begin":246,"end":250},"obj":"http://www.ebi.ac.uk/efo/EFO_0000934"},{"id":"T6","span":{"begin":299,"end":302},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"}],"text":"agents may facilitate viral disease; thus, they should not be used in high-risk patients with cardiovascular disease. Based on the anti-inflammatory benefits of the upregulation of the ACE2/Ang1-7/Mas axis and previously demonstrated benefits of lung function improvement in SARS-CoV infections, it has been hypothesized that the benefits of treatment with "}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T1","span":{"begin":94,"end":116},"obj":"Phenotype"}],"attributes":[{"id":"A1","pred":"hp_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/HP_0001626"}],"text":"agents may facilitate viral disease; thus, they should not be used in high-risk patients with cardiovascular disease. Based on the anti-inflammatory benefits of the upregulation of the ACE2/Ang1-7/Mas axis and previously demonstrated benefits of lung function improvement in SARS-CoV infections, it has been hypothesized that the benefits of treatment with "}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T22","span":{"begin":0,"end":6},"obj":"CHEBI:48561;CHEBI:48561"},{"id":"T23","span":{"begin":22,"end":27},"obj":"NCBITaxon:10239"},{"id":"T24","span":{"begin":94,"end":108},"obj":"UBERON:0004535"},{"id":"T25","span":{"begin":185,"end":189},"obj":"G_3;PG_10;PR:000003622"},{"id":"T26","span":{"begin":190,"end":194},"obj":"PR:000036013"},{"id":"T27","span":{"begin":246,"end":250},"obj":"UBERON:0002048"},{"id":"T28","span":{"begin":275,"end":283},"obj":"SP_10"},{"id":"T23807","span":{"begin":0,"end":6},"obj":"CHEBI:48561;CHEBI:48561"},{"id":"T85043","span":{"begin":22,"end":27},"obj":"NCBITaxon:10239"},{"id":"T68089","span":{"begin":94,"end":108},"obj":"UBERON:0004535"},{"id":"T69502","span":{"begin":185,"end":189},"obj":"G_3;PG_10;PR:000003622"},{"id":"T7389","span":{"begin":190,"end":194},"obj":"PR:000036013"},{"id":"T3955","span":{"begin":246,"end":250},"obj":"UBERON:0002048"},{"id":"T22854","span":{"begin":275,"end":283},"obj":"SP_10"}],"text":"agents may facilitate viral disease; thus, they should not be used in high-risk patients with cardiovascular disease. Based on the anti-inflammatory benefits of the upregulation of the ACE2/Ang1-7/Mas axis and previously demonstrated benefits of lung function improvement in SARS-CoV infections, it has been hypothesized that the benefits of treatment with "}

{"project":"LitCovid-PubTator","denotations":[{"id":"29","span":{"begin":185,"end":189},"obj":"Gene"},{"id":"30","span":{"begin":190,"end":196},"obj":"Gene"},{"id":"34","span":{"begin":80,"end":88},"obj":"Species"},{"id":"37","span":{"begin":22,"end":35},"obj":"Disease"},{"id":"38","span":{"begin":94,"end":116},"obj":"Disease"},{"id":"39","span":{"begin":275,"end":294},"obj":"Disease"}],"attributes":[{"id":"A29","pred":"tao:has_database_id","subj":"29","obj":"Gene:59272"},{"id":"A30","pred":"tao:has_database_id","subj":"30","obj":"Gene:284"},{"id":"A34","pred":"tao:has_database_id","subj":"34","obj":"Tax:9606"},{"id":"A37","pred":"tao:has_database_id","subj":"37","obj":"MESH:D001102"},{"id":"A38","pred":"tao:has_database_id","subj":"38","obj":"MESH:D002318"},{"id":"A39","pred":"tao:has_database_id","subj":"39","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"agents may facilitate viral disease; thus, they should not be used in high-risk patients with cardiovascular disease. Based on the anti-inflammatory benefits of the upregulation of the ACE2/Ang1-7/Mas axis and previously demonstrated benefits of lung function improvement in SARS-CoV infections, it has been hypothesized that the benefits of treatment with "}